The Biotech Growth Trust PLC
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create … Read more
The Biotech Growth Trust PLC (BIOG) - Total Liabilities
Latest total liabilities as of September 2025: GBX32.10 Million GBX
Based on the latest financial reports, The Biotech Growth Trust PLC (BIOG) has total liabilities worth GBX32.10 Million GBX as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
The Biotech Growth Trust PLC - Total Liabilities Trend (2004–2025)
This chart illustrates how The Biotech Growth Trust PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
The Biotech Growth Trust PLC Competitors by Total Liabilities
The table below lists competitors of The Biotech Growth Trust PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nodechain Inc
PINK:NODC
|
USA | $102.24K |
Liability Composition Analysis (2004–2025)
This chart breaks down The Biotech Growth Trust PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how The Biotech Growth Trust PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for The Biotech Growth Trust PLC (2004–2025)
The table below shows the annual total liabilities of The Biotech Growth Trust PLC from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | GBX5.42 Million | -89.18% |
| 2024-03-31 | GBX50.11 Million | +65.84% |
| 2023-03-31 | GBX30.22 Million | -9.09% |
| 2022-03-31 | GBX33.24 Million | -30.84% |
| 2021-03-31 | GBX48.06 Million | +34.95% |
| 2020-03-31 | GBX35.62 Million | +59.31% |
| 2019-03-31 | GBX22.36 Million | -22.04% |
| 2018-03-31 | GBX28.68 Million | +119.20% |
| 2017-03-31 | GBX13.08 Million | -71.91% |
| 2016-03-31 | GBX46.58 Million | -12.50% |
| 2015-03-31 | GBX53.23 Million | +32.46% |
| 2014-03-31 | GBX40.19 Million | +80.86% |
| 2013-03-31 | GBX22.22 Million | +287.29% |
| 2012-03-31 | GBX5.74 Million | -60.10% |
| 2011-03-31 | GBX14.38 Million | +14.99% |
| 2010-03-31 | GBX12.51 Million | +192.51% |
| 2009-03-31 | GBX4.28 Million | +117.01% |
| 2008-03-31 | GBX1.97 Million | -47.16% |
| 2007-03-31 | GBX3.73 Million | +48.47% |
| 2006-03-31 | GBX2.51 Million | +754.08% |
| 2005-03-31 | GBX294.00K | -36.36% |
| 2004-03-31 | GBX462.00K | -- |